Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Accumulated Expenses (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Accumulated Expenses for 6 consecutive years, with $46.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 13.96% to $46.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.5 million through Dec 2025, up 13.96% year-over-year, with the annual reading at $46.5 million for FY2025, 13.96% up from the prior year.
  • Accumulated Expenses hit $46.5 million in Q4 2025 for Lyell Immunopharma, up from $29.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $46.5 million in Q4 2025 to a low of $21.4 million in Q2 2022.
  • Historically, Accumulated Expenses has averaged $28.2 million across 5 years, with a median of $28.0 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: dropped 16.32% in 2022 and later surged 45.14% in 2024.
  • Year by year, Accumulated Expenses stood at $29.1 million in 2021, then fell by 1.04% to $28.8 million in 2022, then decreased by 2.19% to $28.1 million in 2023, then surged by 45.14% to $40.8 million in 2024, then rose by 13.96% to $46.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for LYEL at $46.5 million in Q4 2025, $29.3 million in Q3 2025, and $28.0 million in Q2 2025.